Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Glaucoma signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision, and reddening of the eye.

The Glaucoma pipeline drugs market research report provides an analysis of the Glaucoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.

Key Targets of the Glaucoma Pipeline Drugs Market

Some of the targets of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor, Rho Kinase, Beta 1 Adrenergic Receptor, Cannabinoid Receptor 2, Beta 2 Adrenergic Receptor, Cannabinoid Receptor 1, Soluble Guanylate Cyclas, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 2 Adrenergic Receptor, Amyloid Beta A4 Protein, and Angiopoietin 1 Receptor among others.

Glaucoma Pipeline Drugs Market, by Key Targets

Glaucoma Pipeline Drugs Market, by Key Targets

For more insights on key targets, download a free report sample

Key Mechanisms of Action in the Glaucoma Pipeline Drugs Market

The key mechanisms of action of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Rho Kinase Inhibitor, Beta 1 Adrenergic Receptor Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Soluble Guanylate Cyclase Activator, Beta 2 Adrenergic Receptor Antagonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha 2 Adrenergic Receptor Agonist, and Angiopoietin 1 Receptor Agonist.

Glaucoma Pipeline Drugs Market, by Key Mechanisms of Action

Glaucoma Pipeline Drugs Market, by Key Mechanisms of Action

For more insights on key mechanisms of action, download a free report sample

Key Routes of Administration in the Glaucoma Pipeline Drugs Market

The routes of administration in the Glaucoma pipeline drugs market are ophthalmic, intraocular, intravitreal, oral, parenteral, intravenous, topical, transdermal, subcutaneous, inhalational, nasal, and sublingual among others.

Glaucoma Pipeline Drugs Market, by Routes of Administration

Glaucoma Pipeline Drugs Market, by Routes of Administration

For more insights on routes of administration, download a free report sample

Key Molecule Types in the Glaucoma Pipeline Drugs Market

The molecule types in the Glaucoma pipeline drugs market are Small Molecule, Gene Therapy, Antisense RNAi Oligonucleotide, Monoclonal Antibody, Recombinant Protein, Synthetic Peptide, and Biologic.

Glaucoma Pipeline Drugs Market, by Molecule Types

Glaucoma Pipeline Drugs Market, by Molecule Types

For more insights on molecule type, download a free report sample

Key Companies in the Glaucoma Pipeline Drugs Market

Some of the key companies in the Glaucoma pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Intratus Inc, Graybug Vision Inc, Ocular Therapeutix Inc, Aerie Pharmaceuticals Inc, Astellas Pharma Inc, DHP Korea Co Ltd, Laboratoires Thea SA, and SIFI SpA among others.

Glaucoma Pipeline Drugs Market, by Companies

Glaucoma Pipeline Drugs Market, by Companies

For more insights on companies, download a free report sample

Glaucoma Pipeline Drugs Market Report Overview

Key Targets Prostaglandin F2 Alpha Receptor, Rho Kinase, Beta 1 Adrenergic Receptor, Cannabinoid Receptor 2, Beta 2 Adrenergic Receptor, Cannabinoid Receptor 1, Soluble Guanylate Cyclas, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 2 Adrenergic Receptor, Amyloid Beta A4 Protein and Angiopoietin 1 Receptor
Key Mechanisms of Action Prostaglandin F2 Alpha Receptor Agonist, Rho Kinase Inhibitor, Beta 1 Adrenergic Receptor Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Soluble Guanylate Cyclase Activator, Beta 2 Adrenergic Receptor Antagonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha 2 Adrenergic Receptor Agonist, and Angiopoietin 1 Receptor Agonist
Key Routes of Administration Ophthalmic, Intraocular, Intravitreal, Oral, Parenteral, Intravenous, Topical, Transdermal, Subcutaneous, Inhalational, Nasal and Sublingual
Key Molecule Types Small Molecule, Gene Therapy, Antisense RNAi Oligonucleotide, Monoclonal Antibody, Recombinant Protein, Synthetic Peptide, and Biologic
Key Companies NicOx SA, Santen Pharmaceutical Co Ltd, Intratus Inc, Graybug Vision Inc, Ocular Therapeutix Inc, Aerie Pharmaceuticals Inc, Astellas Pharma Inc, DHP Korea Co Ltd, Laboratoires Thea SA, and SIFI SpA

Scope 

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

4B Technologies (Suzhou) Co Ltd
Aadi Bioscience Inc
AbbVie Inc
AC Immune SA
Adtech Pharma Inc
Advanced Vision Technologies (New York)
Aerie Pharmaceuticals Inc
Amgen Inc
Annexon Inc
Annovis Bio Inc
APIRx Pharmaceuticals USA LLC
Arctic Vision Shanghai Biotechnology Co Ltd
Astellas Pharma Inc
Avirmax Inc
Betaliq Inc
Bial - Portela & Ca SA
Biozeus Pharmaceutical SA
Broadwing Bio
BSIM Therapeutics SA
Calpain Therapeutics Pty Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Character Biosciences Co
Chong Kun Dang Pharmaceutical Corp
Cloudbreak Therapeutics LLC
Connexin Therapeutics Inc
Curigin Co Ltd
D. Western Therapeutics Institute Inc
Deha Pharmaceutical LLC
DHP Korea Co Ltd
Disarm Therapeutics Inc
Dompe Farmaceutici SpA
DTx Pharma Inc
Emerald Organic Products Inc
Emmecell LLC
Evotec SE
Eye Bio Korea Co Ltd
EyePoint Pharmaceuticals Inc
Eyevensys SAS
FasT Biopharma Ltd
Future Medicine Co Ltd
Galimedix Therapeutics Ltd
Glaukos Corp
Graybug Vision Inc
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Gurus BioPharm Inc
Handok Inc
HitGen Inc
HK inno.N Corp
ID Pharma Co Ltd
Iduna Therapeutics Inc
Ildong Pharmaceutical Co Ltd
InMed Pharmaceuticals Inc
Intratus Inc
Isarna Therapeutics GmbH
jCyte Inc
Jenivision Inc
Kodiak Sciences Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kyorin Pharmaceutical Co Ltd
Laboratoires Thea SA
Laboratorios Salvat SA
Laboratorios Sophia SA de CV
LayerBio Inc
Lee's Pharmaceutical Holdings Ltd
Life Biosciences LLC
Luminus Biosciences Inc
Matrix Biomed Inc
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
MimeTech Srl
Mitotech SA
MyX Therapeutics Inc
NeurAegis Inc
Neuraly Inc
Neurim Pharmaceuticals Ltd
Neurizon Pharma GBR
Neurophth Therapeutics Inc
Neuroptika Inc
NeuroScientific Biopharmaceuticals Ltd
Nexel Co Ltd
NicOx SA
NoNO Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
Novoron Bioscience Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Oculis SA
Oculo Therapy LLC
Ocuphire Pharma Inc
Oncolys BioPharma Inc
ONL Therapeutics Inc
Perceive Biotherapeutics Inc
pH Pharma Co Ltd
PharmaDrug Inc
Pinotbio Inc
PolyActiva Pty Ltd
Profarma
Q BioMed Inc
Qlaris Bio Inc
Quark Pharmaceuticals Inc
Qurgen Inc
Radikal Therapeutics Inc
Rebio Technologies Ltd
Rebus Holdings Inc
Regeneron Pharmaceuticals Inc
ReNetX Bio
Retinset SL
Reven Holdings Inc
Ripple therapeutics Corp
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
SIFI SpA
Skye Bioscience Inc
Stuart Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Sun Pharmaceutical Industries Ltd
Sustained Nano Systems LLC
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TALLC Inc
Tarsius Pharma Ltd
TearClear Corp
Teraclon IDF SL
TikoMed AB
Toa Eiyo Ltd
Topadur Pharma AG
ViSci Ltd
Visus Therapeutics Inc
Viva Vision Biotech
Whitecap Biosciences LLC
Xilingyuan Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glaucoma – Overview

Glaucoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Glaucoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glaucoma – Companies Involved in Therapeutics Development

Glaucoma – Drug Profiles

Glaucoma – Dormant Projects

Glaucoma – Discontinued Products

Glaucoma – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Glaucoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Glaucoma – Dormant Projects, 2022

Glaucoma – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Glaucoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the targets of the Glaucoma pipeline drugs market?

    Some of the targets of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor, Rho Kinase, Beta 1 Adrenergic Receptor, Cannabinoid Receptor 2, Beta 2 Adrenergic Receptor, Cannabinoid Receptor 1, Soluble Guanylate Cyclas, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Alpha 2 Adrenergic Receptor, Amyloid Beta A4 Protein and Angiopoietin 1 Receptor.

  • What are the mechanisms of action of the Glaucoma pipeline drugs market?

    The key mechanism of action of the Glaucoma pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Rho Kinase Inhibitor, Beta 1 Adrenergic Receptor Antagonist, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Soluble Guanylate Cyclase Activator, Beta 2 Adrenergic Receptor Antagonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Amyloid Beta A4 Protein Inhibitor, Alpha 2 Adrenergic Receptor Agonist, and Angiopoietin 1 Receptor Agonist.

  • What are the routes of administration in the Glaucoma pipeline drugs market?

    The routes of administration in the Glaucoma pipeline drugs market are ophthalmic, intraocular, intravitreal, oral, parenteral, intravenous, topical, transdermal, subcutaneous, inhalational, nasal and sublingual.

  • What are the molecule types in the Glaucoma pipeline drugs market?

    The molecule types in the Glaucoma pipeline drugs market are Small Molecule, Gene Therapy, Antisense RNAi Oligonucleotide, Monoclonal Antibody, Recombinant Protein, Synthetic Peptide, and Biologic.

  • Which are the key companies in the Glaucoma pipeline drugs market?

    Some of the key companies in the Glaucoma pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Intratus Inc, Graybug Vision Inc, Ocular Therapeutix Inc, Aerie Pharmaceuticals Inc, Astellas Pharma Inc, DHP Korea Co Ltd, Laboratoires Thea SA, and SIFI SpA among others.

Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.